You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

  • Technology appraisal guidance
  • Reference number: TA258
  • Published:  27 June 2012
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix b - proposal paper presented to the Institute's Guidance Executive

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix b - proposal paper presented to the Institute's Guidance Executive Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix b - proposal paper presented to the Institute's Guidance Executive
13 October 2014
(365.47 Kb 46 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 10 October 2014

Back to top